Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 April 2010
Topic area
  • Musculoskeletal

Scoped within batch 10

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Tonya Gillis
Executive Lead: Andrew Dillon
Project manager: Jeremy Powell
Technical Lead: Whitney Miller


Manufacturers/sponsors Rituximab (Roche Products)
Others Bradford and Airedale Teaching PCT
  Department of Health
  NHS Hertfordshire
  Welsh Assembly Government
Patient/carer groups Action on Pain
  Afiya Trust
  Arthritic Association
  Arthritis & Musculoskeletal Alliance (ARMA)
  Arthritis Care
  Black Health Agency
  Chinese National Healthy Living Centre
  Counsel and Care
  Equalities National Council
  Leonard Cheshire Disability
  Muslim Council of Britain
  Muslim Health NetworkNational Rheumatoid Arthritis Society
  Pain Concern
  Pain Relief Foundation
  Royal Association for Disability & Rehabilitation (RADAR)
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association for Services to the Elderly
  British Geriatrics Society
  British Health Professionals in Rheumatology
  British Institute of Musculoskeletal Medicine
  British Institute of Radiology
  British Orthopaedic Association
  British Pain Society
  British Society for Rheumatology
  British Society of Rehabilitation Medicine
  Physiotherapy Pain Association
  Primary Care Rheumatology Society
  Rheumatoid Arthritis Surgical Society
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine â?? Intellectual Disabilities Forum
  Society and College of Radiographers
  United Kingdom Clinical Pharmacy Association
Comparator manufacturer(s) AAH Pharmaceuticals (azathioprine, sulfasalazine, penicillamine)
  Abbott Laboratories (adalimumab)
  Actavis (azathioprine, sulfasalazine, penicillamine)
  Almus Pharmaceuticals (sulfasalazine)
  Arrow Generics (azathioprine)
  AstraZeneca (chloroquine)
  Focus Pharmaceuticals (azathioprine)
  Genesis Pharmaceuticals (sulfasalazine)
  GlaxoSmithKline (azathioprine)
  Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine)
  Metwest Pharmaceuticals (sulfasalazine)
  Mylan (azathioprine, sulfasalazine, penicillamine)
  Novartis (ciclosporin)
  Pfizer (sulfasalazine)
  Rosemont Pharmaceuticals (sulfasalazine)
  Sandoz (azathioprine)
  Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
  Schering-Plough (infliximab, golimumab)
  Teva UK (azathioprine, sulfasalazine, penicillamine)
  Tillomed Laboratories (azathioprine)
  UCB Pharma (certolizumab pegol)
  Wyeth Pharmaceuticals (etanercept)
Evidence Review Group West Midlands Health Technology Assessment Collaboration
  National Institute for Health Research Health Technology Assessment Programme
  Associated Guideline Groups
  National Clinical Guideline Centre
  Associated Public Health Groups
General Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Commissioning Support Appraisals Service
  Department of Health, Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  NHS Quality Improvement Scotland
  Public Health Wales NHS Trust
  Scottish Medicines Consortium
Relevant research groups Arthritis Research Campaign
  Chronic Pain Policy Coalition
  MRC Clinical Trials Unit
  National Institute for Health Research
  Policy Research Institute on Ageing and Ethnicity
  Research Institute for the Care of Older People


Key events during the development of the guidance:

Date Update
22 March 2011

The manufacturer has informed us that they will not be seeking a license for this particular indication at the present time.

NICE has therefore decided to suspend this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.”

For further information on our processes and methods, please see our CHTE processes and methods manual